Collectively, these results indicate that targeted inhibition of 14-3-3η/NF-κB by imICA prevented DEHP-elevated IL-6 and CXCL1, leading to the reversal of DEHP-induced HOD in male mice. The gene discussed is CXCL1; the disease is hypopigmentation, organomegaly, and delayed myelination and development.